KRON News

After a fast and furious week of activity, the IPO market is slated for a brief intermission in the coming week due to the approaching presidential election. Currently, there are no regular way US IPOs scheduled for the first week of November, though it is possible we could see several SPAC pricings.  Even though the calendar is empty, the IPO market slowdown for election...read more

Seven IPOs and 10 SPACs went public this past week. The IPO pipeline remained active, with 11 IPOs and 22 SPACs submitting initial filings. Phase 2 biotech Kronos Bio (KRON) priced above the range to raise $250 million at a $1.1 billion market cap. The biotech is developing therapies targeting dysregulated transcription factors for leukemia and solid tumor...read more

Kronos Bio, a Phase 2 biotech developing kinase inhibitors for leukemia and solid tumors, raised $250 million by offering 13.2 million shares at $19, above the range of $16 to $18. The company originally planned to offer 10.3 million shares at the same range before revising its terms on Thursday morning. At pricing, the company raised 12% more in proceeds than anticipated. ...read more

Kronos Bio, a Phase 2 biotech developing kinase inhibitors for leukemia and solid tumors, raised the proposed deal size for its upcoming IPO on Thursday. The San Mateo, CA-based company now plans to raise $224 million by offering 13.2 million shares at a price range of $16 to $18. The company had previously filed to offer 10.3 million shares at the same range. At the increased...read more